CSF3 and neutropenia: In this study, mucositis (p = 0.004), neurotoxicity (p = 0.038), neutropenia (p = 0.02), dose reductions (p = 0.005), the need for granulocyte colony-stimulating factor support (p = 0.005), toxicity-related treatment discontinuation (p = 0.001), and chemotherapy-related toxic deaths (p = 0.013) were reported to be associated with GPS.